Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

Abstract HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were ra...

Full description

Bibliographic Details
Main Authors: Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie Jin, Huizheng Bao, Xin Du, Hui Zhou, Gan Fu, Yuankai Shi
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
HLX01
Rituximab biosimilar
DLBCL
Overall survival
HanliKang®
Online Access:https://doi.org/10.1186/s12885-024-11876-9

Internet

https://doi.org/10.1186/s12885-024-11876-9

Similar Items